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Evolving Concepts in the Management of Newly
Diagnosed Epithelial Ovarian Cancer
Charlie Gourley, PhD1 and Michael A. Bookman, MD2
INTRODUCTION
Clinical research over the last 30 years has delivered
meaningful improvements in progression-free survival
(PFS), overall survival (OS), and quality of life for
women with epithelial ovarian cancer (EOC), as
highlighted in Figure 1.1-3 However, EOC remains
a highly lethal disease because of peritoneal dis-
semination at diagnosis, rapid development of che-
motherapy resistance, and evasion of host immune
response. Minor reductions in disease-specific mor-
tality over the last decade are more likely attributable to
the use of oral contraceptives, changes in parity, and
the recent expansion of risk-reducing surgery among
women from high-risk genetic backgrounds, together
with a reduction in long-term hormone replacement,
reducing the incidence of EOC.4-6
Primary treatment generally incorporates surgical
cytoreduction and chemotherapy with a combination of
carboplatin and a taxane (paclitaxel or docetaxel),
achieving clinical complete remission inmore than 80%
of women. Prior research focused on optimization of
conventional chemotherapy (dose-intensity, dose den-
sity, incorporation of different agents), timing of cyto-
reductive surgery, use of regional (intraperitoneal [IP])
drug administration, and extended maintenance with
cytotoxic chemotherapy during remission. With the
possible exception of IP drug administration and the use
of a dose-dense once-per-week schedule of paclitaxel,
none of these carefully conducted, historical phase III
trials established a new standard of care.
In parallel with other cancers, there has been an ex-
plosion of data related to the etiology, clinical biology,
and molecular characteristics of EOC.7-9 We now
understand that EOC is a broad categorization en-
compassing tumors originating from the fallopian tube,
ovarian surface, and cellular rests within the peritoneal
cavity, including endometriosis and synchronous tu-
mors involving the endometrial cavity. The ovaries are
a favored site of tumor growth, with over 80% bilateral
involvement, and large adnexal tumors are often the
dominant clinical and pathologic findings, even if the
tumor originated from microscopic foci within the
fallopian tube or other sites.
High-grade serous carcinoma (HGSC) is the most
common histology, followed by endometrioid, clear
cell (CCC), low-grade serous, and mucinous carcino-
mas. In addition, carcinosarcoma (or mixed Mu¨llerian
tumor) is now recognized to be an aggressive clonal
epithelial malignancy with focal mesenchymal differ-
entiation, attributed to epithelial-to-mesenchymal
transition. Each histology has been associated with
characteristic molecular features in terms of loss of
specific tumor suppressor genes, defects in high-
fidelity DNA repair, and activation of signal trans-
duction or downstream pathways. However, unlike in
other cancers, reproducible driver mutations are un-
common, limiting the success of therapeutics targeting
classic oncogenic signal transduction pathways.
In HGSC and CC carcinoma, there is frequent acti-
vation of hypoxia-driven proangiogenic pathways,
which trigger increased production of vascular en-
dothelial growth factor (VEGF), and this is largely re-
sponsible for capillary leak resulting in increased
interstitial pressure, ascites, and pleural effusions.
These VEGF-mediated effects are amenable to tar-
geting using conventional chemotherapy, anti-VEGF
monoclonal antibodies (bevacizumab), or small-
molecule VEGF receptor (VEGFR) tyrosine kinase in-
hibitors (TKIs).
In HGSC, as a consequence of homologous re-
combination deficiency (HRD) and replication stress,
there is an opportunity for treatment with inhibitors of
poly (ADP-ribose) polymerase (PARP). In addition,
DNA mismatch repair and microsatellite instability
have been described in a minority of endometrioid and
clear cell tumors, but they are uncommon in HGSC,
and it is unusual to identify high mutation burden
scores in EOC, limiting the activity of single-agent
immune checkpoint inhibitors.
ADJUVANT THERAPY FOR EARLY-STAGE DISEASE
The importance of accurate surgical staging is
recognized,10-13 together with the hope that detec-
tion of occult metastatic disease could be enhanced
with high-resolution functional imaging and/or intra-
operative molecular probes to guide surgical in-
terventions. However, the clinical biology of HGSC is
characterized by early peritoneal dissemination, and
a majority of recurrences with seemingly early-stage
disease result from HGSC. In contrast, nonserous
tumors (CC, endometrioid, and mucinous) are more
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commonly diagnosed in early stages, less likely associated
with occult peritoneal implants, and more likely to be cured
with primary surgery. These differences are perhaps most
clearly illustrated in a retrospective analysis of GOG (Gy-
necologic Oncology Group) 157, which compared three
versus six cycles of adjuvant chemotherapy.14 In HGSC,
improved recurrence-free survival was demonstrated with
six cycles, and it is reasonable to recommend six cycles for
women with seemingly early-stage HGSC. Among non-
serous tumors, no difference was observed between three
versus six cycles, although this study was not designed to
assess a noninferiority end point.
• Women with seemingly early-stage HGSC should
generally receive six cycles of adjuvant chemotherapy.
• The role of adjuvant chemotherapy in early-stage
nonserous EOC remains to be established. It should
be individualized in accordance with histology, risk
factors, adequacy of surgical staging, comorbidities,
and likelihood of response to platinum-based che-
motherapy. If adjuvant therapy is administered, three
to six cycles are generally recommended and can be
considered as tolerated.
TIMING AND SCOPE OF CYTOREDUCTIVE SURGERY
With improved diagnostics, high-resolution cross-sectional
and functional imaging, and advanced surgical skills, it is
reasonable to expect a modest shift toward lower tumor
burden at diagnosis and higher rates of optimal (micro-
scopic) primary cytoreductive surgery (PCS). However,
approximately 40% of women will continue to present with
malnutrition, bowel dysfunction, extensive upper abdomi-
nal or extraperitoneal disease, large-volume ascites, ad-
vanced age, and associated comorbidities. Many of these
patients will receive neoadjuvant chemotherapy (NACT)
with consideration of interval cytoreductive surgery, on the
basis of outcomes from multiple randomized trials in high-
risk disease.
The goal of cytoreductive surgery remains the complete
resection of macroscopic disease. Of note, a large retro-
spective analysis of primary surgery suggests that long-term
benefits associated with complete cytoreduction are more
apparent among women with low disease burden scores at
diagnosis.15 Patients with complete cytoreduction and high
disease burden scores had outcomes similar to those of
patients with suboptimal (macroscopic) cytoreduction. As
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FIG 1. Trends in long-term outcomes in relation to key clinical trials and discoveries. Improvements in US 5-year overall survival (OS) are likely
multifactorial, related to diagnostic modalities, access to supportive care, and treatment interventions for primary and recurrent disease. Landmark
ovarian cancer discoveries and trial results are plotted along the ovarian cancer mortality curve. USmortality rates from 1930 to present day for breast,
uterine (cervix and corpus combined), lung (including bronchus), and ovarian cancers (including fallopian tube and peritoneal) demonstrate amodest
downward trend for women with ovarian cancer beginning approximately 2005, whichmay reflect changes in use of oral contraceptives and hormonal
therapy, documentation of high-risk families, and implementation of risk-reducing surgery. US ovarian cancer incidence (1975 onward) also trended
downward during this time period. Data adapted.1-3 AGO, Arbeitsgemeinschaft Gyna¨kologische Onkologie; MRC CHORUS, Medical Research Council
Chemotherapy Or Upfront Surgery; EORTC, European Organisation for Research and Treatment of Cancer; GOG, Gynecologic Oncology Group;
ICON7, International Collaborative Ovarian Neoplasm study 7; IP, intraperitoneal; JGOG, Japanese Gynecologic Oncology Group; NACT, neoadjuvant
chemotherapy; OS, overall survival; SOLO1, Study of Olaparib maintenance therapy in Ovarian cancer after first-line therapy.
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such, the impact of aggressive primary surgery in women
with high disease burden remains to be established,
pending results from TRUST (Trial on Radical Upfront
Surgery in Advanced Ovarian Cancer).16
Triage of patients for PCS or NACT with consideration of
interval cytoreductive surgery can be challenging because
of imaging studies, which may under- or overestimate the
extent of invasive or metastatic disease. Validated models
can predict the likelihood of achieving complete primary
cytoreduction on the basis of clinical factors.17 Other
models have incorporated laparoscopic assessment of
disease burden.18,19 In addition, molecular markers related
to transforming growth factor b pathway activation and
invasive mesenchymal biology can predict for a lower
likelihood of achieving complete cytoreduction, but they are
not yet sufficiently robust to drive surgical decisions,20 and
we await the emergence of models that integrate molecular
and clinical factors.
• Although efforts to refine the integration of surgery and
chemotherapy are important, the practical limitations
of conventional chemotherapy and surgery in the
setting of advanced disease are well recognized, and
additional strategies are needed to substantially im-
prove long-term outcomes for a majority of patients.
PRIMARY CHEMOTHERAPY
The development of cisplatin was pivotal in the evolution of
early chemotherapy regimens for EOC, although compli-
cated by significant hematologic and nonhematologic
toxicities. Two phase III trials demonstrated improved
OS with a combination of cisplatin and paclitaxel (as
a 24-hour infusion) compared with cisplatin and
cyclophosphamide21,22 at a time when investigational
paclitaxel was in limited supply and not available outside
a clinical trial. Substitution of carboplatin for cisplatin and
use of a 3-hour outpatient paclitaxel infusion reduced
nonhematologic toxicity and improved overall tolerability,
while maintaining therapeutic efficacy.23-25
Historical questions remain regarding the advantage
of combination regimens compared with sequential
single-agents (eg, carboplatin followed by paclitaxel at
progression), especially in higher-risk or frail elderly
populations.26,27 However, combinations of paclitaxel with
carboplatin are unusual, maintaining the capability to safely
administer full doses of both drugs on a 21-day schedule,
which has been attributed, in part, to a platelet-sparing
effect of paclitaxel on carboplatin-mediated thrombocyto-
penia.28 In patients age older than 70 years, a number of
studies have demonstrated an association between frailty
scoring systems, such as comprehensive geriatric as-
sessment,29 instrumental activities of daily living,30 or geri-
atric vulnerability score,31 and completion of chemotherapy,
development of toxicity, or OS. The EWOC-1 (Elderly Women
Ovarian Cancer) study is a prospective randomized study
that is currently investigating the extent of benefit and
toxicity resulting from the addition of paclitaxel to single-
agent carboplatin in vulnerable patients defined by a geri-
atric vulnerability score greater than 3.
Carboplatin is largely cleared through the kidneys, and
achieving a targeted area under the curve (AUC) of con-
centration 3 time depends on the glomerular filtration rate
(GFR). GFR is no longer usually measured but instead
imputed on the basis of the estimated creatinine clearance
(CrCl) using an established formula, which relies on a spot
measure of serum creatinine. This has proven to be
problematic, because most formulae were derived from
male patients with near-normal renal function using older
methods to standardize creatinine measurements. In ad-
dition, women with advanced-stage ovarian cancer typically
have reduced nonphysiologic creatinine levels because of
decreased muscle mass, malnutrition, decreased distal
tubal reabsorption, and other factors, compounded by
changes in laboratory reporting on the basis of traceable
standards with isotope dilution mass spectrometry (IDMS),
which tends to lower reported creatinine values, generating
false high estimated CrCl, with risk of carboplatin over-
dosage. Current US recommendations cap the estimated
CrCl to reduce risk; we await better validatedmethods using
IDMS.32,33
After a number of international phase III trials involving
more than 12,000 women, there is no prospective evidence
that higher platinum dose-intensity (with or without he-
matopoietic growth factor support) extended cycles of
chemotherapy, maintenance chemotherapy, incorporation
of a third cytotoxic agent, or substitution of cytotoxic agents
will improve long-term outcomes for unselected patients
with HGSC.34-40 These limitations of conventional cytotoxic
chemotherapy have largely been attributed to the rapid
emergence of drug resistance to platinum compounds,
natural products, and nucleoside analogs through multiple
independent cellular pathways. As such, standard-dose
carboplatin and paclitaxel remains a well-tolerated and
effective primary treatment regimen and is consistently
recommended as a reference arm for trials in advanced-
stage disease by the Gynecologic Cancer InterGroup.41
Questions remain regarding optimal dose selection, man-
agement of hematologic toxicity, and use of granulocyte
colony-stimulating factors. In a retrospective analysis of
patients enrolled in a phase III trial with advanced-stage
disease, dose modification was associated with a reduction
in PFS and OS, but also with confounding variables such as
performance status, stage, histology, and residual disease
in an adjusted multivariable analysis.42 Use of granulocyte
colony-stimulating factors, with or without associated dose
modification, did not have a discernable impact on PFS or
OS. When considered together with a large body of negative
data from prospective randomized trials evaluating plati-
num dose-intensity, it is likely that patients with dose
modifications also had other prognostic factors contributing
to increased risk, rather than there being a direct
Journal of Clinical Oncology 3
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relationship between minor variations in carboplatin AUC
and survival.
• Within established ranges (AUC, 5 or 6), carboplatin
dosing can be individualized depending on vital organ
function, comorbidities, and tolerance. Similarly,
paclitaxel can be administered in the range of 135 to
175 mg/m2 as a 3-hour infusion, based largely on
assessment of risk factors for peripheral neuropathy.
• Aberrant low creatinine levels and IDMS reporting
should be considered when estimating GFR. In the
absence of a measured GFR or a validated estimated
GFR that is accurate at low creatinine levels, physio-
logic limits should be applied for patient safety (min-
imum creatinine, 0.70 mg/dL; estimated GFR not
higher than 125 mL per minute).
IP CHEMOTHERAPY
Given that ovarian cancer is largely a locoregional disease
with peritoneal dissemination predominating over visceral
metastases, the idea of delivering a high local dose of
cytotoxic therapy is appealing. However, peritoneal tumors
are characterized by high interstitial pressures attributable
to VEGF-mediated capillary leak and the absence of
draining lymphatics, limiting the penetration of diffusion-
limited drugs, such as cisplatin. The initial proof of principle
for IP chemotherapy was provided by GOG 104, comparing
intravenous (IV) cyclophosphamide plus either IV or IP
cisplatin 100 mg/m2.43 This straight comparison favored IP
cisplatin in terms of OS, but at the expense of increased
cisplatin-mediated toxicity in both arms. Of note, a subset
analysis suggested that the benefit was confined to patients
with macroscopic small-volume residual disease, without
benefit in patients with microscopic residual disease,
challenging a number of assumptions. By the time of
publication, the standard of care for first-line therapy had
evolved to cisplatin and paclitaxel, followed by a rapid
transition to carboplatin and paclitaxel, raising questions of
relevance and prompting other trials.
GOG 114 compared IV paclitaxel (135 mg/m2 over
24 hours) and IV cisplatin (75 mg/m2) for six cycles with IV
carboplatin (AUC, 9) for two cycles followed by IV paclitaxel
(135mg/m2 over 24 hours) and IP cisplatin (100mg/m2) for
six cycles (total of eight cycles).44 Although there was
improved efficacy in the IP arm, the study compared dif-
ferent doses and durations of platinum, associated with
increased hematologic toxicity, and was not endorsed by
the authors as practice changing.
GOG 172 then compared IV paclitaxel (135 mg/m2 over
24 hours) with either IV cisplatin (75 mg/m2) or IP cisplatin
(100 mg/m2) followed by IP paclitaxel (60 mg/m2 day 8)
in patients with postoperative residual disease less than
1 cm.45 A significant survival benefit was demonstrated in
favor of the IP arm (median, 66 v 50 months), and this
triggered a National Cancer Institute alert recommending
consideration of IP cisplatin in appropriate patients.
However, the study was challenged on the basis of non-
equivalent platinum dosing and the additional IP paclitaxel
on day 8 (adding a once-per-week paclitaxel component in
the IP arm), limiting conclusions about IV versus IP cis-
platin. However, the median OS in the IP arm was ex-
ceptional, particularly in patients with no visible residual
disease at the end of primary surgery (127 months).46
The most recently reported phase III GOG study (GOG
252) compared three arms, IV paclitaxel (80 mg/m2 once
per week) plus IV carboplatin (AUC 6, once every 3
weeks) with IV paclitaxel (80 mg/m2 once per week) plus
IP carboplatin (AUC 6, once every 3 weeks) with IV
paclitaxel (135 mg/m2 on day1), IP cisplatin (75mg/m2 on
day 2), and IP paclitaxel (60 mg/m2 on day 8).47 The third
arm was a modification of the IP regimen from GOG 172.
In this study, all patients received concomitant and
maintenance bevacizumab (15 mg/kg once every 3
weeks) for a total of 22 cycles. There was no difference in
either PFS or OS among the arms. Unlike prior studies,
GOG 252 permitted limited enrollment of patients with
suboptimal residual disease (as an exploratory end point),
and a subset analysis excluding patients with suboptimal
residual disease also showed no difference in PFS. This
was a large study that accrued rapidly and included
a contemporary chemotherapy foundation. Although
concerns have been expressed regarding the modest
reduction in IP cisplatin (compared with GOG 172), this
improved tolerability and increased the number of IP
cisplatin cycles per patient. Even with this change, the IP
cisplatin arm was associated with increased toxicity
compared with both carboplatin arms.
Concerns have also been raised regarding the inclusion of
bevacizumab. However, in the setting of small-volume
residual disease, bevacizumab would (at most) be asso-
ciated with a modest improvement in PFS, without impact
on OS. In addition, on the basis of data fromGOG 262, there
is no net gain in PFS anticipated from bevacizumab in
combination with once-per-week scheduling of paclitaxel,
as used in GOG 252. On a positive note, the median OS for
all three arms in GOG 252 exceeded the median OS
demonstrated in the IP arm in GOG 172 (and prior IP
studies), consistent with improvements in surgery, che-
motherapy, diagnostic imaging, and supportive care. Data
from a Japanese trial of IP carboplatin without bev-
acizumab (iPocc) will further address these concerns.
• The optimal role of IP cisplatin–based chemotherapy
(without hyperthermia) remains to be established, but
it is an effective regimen that can be considered for
individual patients, after a clear discussion of potential
risks and benefits.
• Median and 5-year OS associated with contempo-
rary IV chemotherapy have improved, compared
with regimens used in earlier clinical trials, with-
out a demonstrated advantage associated with IP
chemotherapy.
4 © 2019 by American Society of Clinical Oncology
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DOSE-DENSE PACLITAXEL WITH CARBOPLATIN
As a single agent in the setting of recurrent disease,
paclitaxel administered once per week seems superior to
paclitaxel administered once every 3 weeks.48 Although this
has been loosely attributed to dose density, there are no
prospective data to validate the importance of paclitaxel
dose-intensity within a clinically tolerable range. Modifi-
cations of paclitaxel infusion duration (1 to 96 hours) and/or
schedule have a clear impact on the spectrum and severity
of host toxicity. In addition, sustained low-level exposure
from once-per-week scheduling (independent of dose) can
have an impact on tumor-associated angiogenesis.49 In this
regard, early trials documented tumor response at levels of
40 mg/m2 per week, compared with a maximally tolerated
single-agent dose of 80 mg/m2 per week.50
In JGOG (Japanese Gynecologic Oncology Group) 3016,
carboplatin in combination with dose-dense once-per-
week paclitaxel (at 80 mg/m2 per week) demonstrated
improved PFS and OS compared with a standard regimen
of once every 3 weeks. Not surprisingly, there was sub-
stantial hematologic toxicity, with frequent dose reductions
and delays, and approximately 40% of patients received
fewer than six cycles.51 These intriguing data were further
evaluated in multiple phase III trials, but with somewhat
discordant results.
MITO-7 (Multicenter Italian Trials in Ovarian Cancer)
compared once-per-week dosing of carboplatin (AUC, 2)
and paclitaxel (60 mg/m2) with a regimen of once every
3 weeks using equivalent cumulative dosing, without any
advantage in PFS or OS. However, the once-per-week
regimen was favored based on a reduction in neuropathy
and hematologic toxicity.52 The contrasting lack of im-
provement with once-per-week dosing raised questions
about potential differences between Asian versus white
populations, as well as the potential negative impact of
fractionating carboplatin, which could be associated with
lower peak drug concentrations and impaired tumor
penetration.
ICON8 was a large (N = 1,565) three-arm trial that compared
standard dosing of once every 3 weeks versus once-per-week
scheduling of both drugs (similar toMITO-7) versus once-per-
week paclitaxel (80 mg/m2) with carboplatin once every
3 weeks (similar to JGOG 3016).53 As anticipated, increased
hematologic toxicity was observed in both once-per-week
paclitaxel regimens. The primary analysis showed no signif-
icant difference in PFS for once-per-week paclitaxel (hazard
ratio [HR], 0.92; 95% CI, 0.77 to 1.09) or once-per-week
carboplatin and paclitaxel (HR, 0.94; 95%CI, 0.79 to 1.12). A
subset analysis demonstrated an overall reduction in median
PFS among patients with delayed cytoreductive surgery
compared with immediate surgery, but drug scheduling had
no impact in either cohort. Mature OS data are pending.
GOG 0262 compared standard dosing of once every
3 weeks versus once-per-week paclitaxel (80 mg/m2) with
carboplatin once every 3 weeks (similar to JGOG 3016), but
with the addition of bevacizumab in both arms.54 Patients
could elect whether to receive bevacizumab, and 19% (n =
112) chose not to receive it. Among the entire intent-to-treat
population and within the subset receiving bevacizumab,
there was no difference in PFS. However, in the cohort that
did not receive bevacizumab, paclitaxel once every 3 weeks
was inferior to all other cohorts, and paclitaxel once per week
without bevacizumab was similar to both arms that included
bevacizumab (Fig 2). This interesting observation suggests
that once-per-week paclitaxel had clinical antiangiogenic
properties, as hypothesized from earlier single-agent studies.
In addition, when blood volume indices were analyzed using
perfusion-weighted computed tomography imagingwithin an
exploratory companion study, ACRIN (American College of
Radiology Imaging Network) 6695, there was an association
between decreased tumor blood flow and improved PFS,
providing additional support regarding the antiangiogenic
impact of once-per-week dosing.55
It is challenging to reconcile these discordant observations
across multiple randomized trials. However, there are some
key points to consider:
• Among Asian patients not receiving bevacizumab, use
of once-per-week dose-dense paclitaxel is preferred,
and we await pharmacogenomic or other data to ex-
plain potential regional differences.56
• If primary chemotherapy is administered in conjunc-
tion with bevacizumab, standard therapy of once every
3 weeks is preferred.
• In patients with high-risk disease receiving NACT, use
of once-per-week paclitaxel is preferred by the authors
to avoid potential toxicity and perioperative compli-
cations associated with bevacizumab. In this setting, it
would be reasonable to consider a lower once-per-
week dose of paclitaxel (60 to 70 mg/m2) to minimize
cumulative hematologic toxicity and peripheral neu-
ropathy while maintaining antiangiogenic potential.
Alternatively, conventional paclitaxel and carboplatin
dosing of once every 3 weeks with bevacizumab can
be considered, omitting bevacizumab in the cycle
before and the cycle after interval debulking surgery.
OPTIMAL USE OF BEVACIZUMAB
Hypoxia-driven proangiogenic pathways are activated in
HGSC, with production of VEGF and other molecules that
promote tumor neovascularization. Tumor capillary beds
are characterized by abnormal branching, incomplete
podocyte coverage, and leaky endothelial junctions, which
contribute to poor tumor perfusion, production of ascites,
and elevated tumor interstitial pressure, effectively limiting
diffusion-based drug penetration. Targeting VEGF can
rapidly reverse these findings, resulting in increased tumor
drug penetration, including platinum agents.57 However,
macromolecules (including monoclonal antibodies) can
exhibit decreased tumor penetration.58,59 There is also
Journal of Clinical Oncology 5
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heterogeneity in the tumor response to bevacizumab-
induced hypoxia, which has been associated with bev-
acizumab resistance.60 Resistance could also be associated
with persistence of small-volume residual disease through
simple diffusion, independent of tumor angiogenesis.61
Questions regarding the dose-response and dose-toxicity
relationships with bevacizumab have not been adequately
explored, with some clinical data suggesting that excessive
vascular remodeling could encourage resistance by reducing
overall tumor perfusion and drug exposure.62
Front-line phase III trials (ICON7 and GOG 0218) have
demonstrated improved PFS with incorporation of con-
current and maintenance bevacizumab, particularly in
patients with bulky high-risk disease.63,64 A subset analysis
of ICON7 also suggested a modest improvement in OS
within a predefined high-risk population.65 However, an
advantage in OS was not observed in GOG 0218, even
though most patients enrolled with high-risk disease. This
seeming discordance has been attributed to different in-
ternational practice patterns, as well as crossover to
commercial bevacizumab postprogression, which was
estimated at 30% in GOG 0218, compared with essentially
no crossover in ICON7.
Randomized phase III trials in recurrent disease (plat-
inum sensitive and resistant) have also documented
improvements in PFS with bevacizumab, achieving lower
HRs, compared with front-line clinical trials.66-68 As noted,
microscopic residual disease (below the diffusion thresh-
old) would be less affected by targeting VEGF, compared
with established macroscopic disease, and this could limit
the clinical effectiveness of front-line interventions. In ad-
dition, the combination of PCS and initial platinum-based
chemotherapy frequently achieves greater than a 90%
reduction in tumor burden, which also eliminates tumor-
associated VEGF production, independent of targeted
interventions.
Although bevacizumab is well tolerated by most patients,
and common toxicities, such as hypertension, can be
medically managed, it clearly contributes to treatment-
related toxicity, financial costs, and complexity of care in
this high-risk population. US Food and Drug Administration
and EuropeanMedicines Agency regulatory approvals have
been obtained in both front-line and recurrent disease
settings, but industry-driven regulatory approvals do not
have the same implications as consensus-based treatment
guidelines or expert recommendations. The following
points merit consideration:
• Among newly diagnosed patients who are candi-
dates for platinum-based chemotherapy and cytore-
ductive surgery, the prolongation of PFS is modest,
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approximately 4 months, in exchange for 6 months of
concurrent therapy and single-agent maintenance
extending beyond a year, without objective evidence of
clinical benefit in terms of quality of life, time without
symptoms or toxicity, or increased OS.
• Although data have validated the clinical role of VEGF
and targeted interventions, it would be reasonable to
plan primary therapy without bevacizumab, reserving
bevacizumab for management of recurrent disease,
when the benefit-risk ratio is maximized. Conversely,
the use of bevacizumab in the first-line setting is also
reasonable, especially if chemotherapy dosing of once
every 3 weeks is used, after consideration of the risks
and benefits of this strategy in the individual patient.
• Among patients with bulky disease, large-volume as-
cites, and/or pleural effusions, bevacizumab could be
integrated with primary chemotherapy to accelerate
clinical response, but the potential role of extended
maintenance therapy would be subject to the same
limitations noted.
• Focused postmarketing (phase IV) studies could ad-
dress questions regarding dose, schedule, duration of
maintenance, and predictive markers.
• Ongoing phase III trials are addressing combinations of
bevacizumab with immune checkpoint inhibitors to
enhance the host antitumor immune response.
TKIS THAT TARGET THE VEGFR PATHWAY
A majority of trials targeting VEGF-mediated angiogenesis
in ovarian cancer have used bevacizumab, although
two international trials led by the Arbeitsgemeinschaft
Gyna¨kologische Onkologie have investigated multikinase
inhibitors in the first-line setting. Pazopanib (an inhibitor of
VEGFR, platelet-derived growth factor receptor, and c-kit)
was evaluated as maintenance in patients with remission
after first-line chemotherapy and resulted in a 5.6-month
PFS advantage without improvement in OS.69 Nintedanib
(an inhibitor of VEGFR, platelet-derived growth factor re-
ceptor, and fibroblast growth factor receptor) was evaluated
as concomitant and maintenance first-line therapy, re-
sulting in a 0.6-month improvement in PFS.70 In contrast
to bevacizumab, an exploratory subset analysis with nin-
tedanib indicated that prolongation of PFS was primarily
associated with small-volume residual disease rather than
large-volume disease. These results further validate the
importance of angiogenic signaling and highlight potential
differences between ligand binding (bevacizumab) and
multikinase receptor inhibition, including organ-specific
toxicity, but they have not had a broad impact on clinical
practice.
ROLE OF PARP INHIBITION
After previous demonstrations of PARP inhibitor efficacy
in both the single-agent monotherapy and maintenance
relapsed disease settings, the SOLO1 study reported
a striking impact of first-line maintenance olaparib among
women with high-grade serous or endometrioid ovarian
cancer associated with a BRCA1 or BRCA2 germline (or
somatic) mutation, in remission after primary surgery and
chemotherapy.71 The HR for PFS was 0.30 (95%CI, 0.23 to
0.41), together with a 3-year advantage in median PFS,
achieving US Food and Drug Administration approval for
BRCA-mutated advanced ovarian cancer in December
2018, although mature OS data are pending. It remains
unclear whether the impact of first-line maintenance
would extend to unselected patients with BRCA wild-type
(WT) tumors or whether there is a role for molecular se-
lection on the basis of HRD or other factors. PRIMA
(ClinicalTrials.gov identifier: NCT02655016) is a phase III
trial evaluating first-line maintenance with niraparib within
a more diverse patient population, including tumors with
and without BRCA mutations. PAOLA-1 (Platine, Avastin
and Olaparib in 1st Line; ClinicalTrials.gov identifier:
NCT02477644) randomly assigns patients to olaparib or
placebo maintenance in combination with bevacizumab
maintenance after first-line platinum-based chemotherapy
plus bevacizumab. These studies, which are expected to
report within the next 12 months, should help to clarify the
extent of benefit within the BRCA WT population and also
shed some light on the utility of the PARP inhibitor bev-
acizumab combination in the first-line setting.
Combinations of PARP inhibitors with platinum-based
chemotherapy have been difficult to develop because
of increased hematologic toxicity, but a phase III trial
of concurrent and maintenance veliparib (GOG 3005;
ClinicalTrials.gov identifier: NCT02470585) has been
completed, and primary end points are anticipated in 2019.
Current considerations include the following:
• Women with germline or somatic BRCA muta-
tions should consider first-line maintenance with
olaparib while in remission after primary surgery and
chemotherapy.
• Assessment of the relative risks and benefits associ-
ated with maintenance PARP inhibition in women
without germline or somatic BRCA mutations awaits
data from ongoing phase III trials.
ONGOING FIRST-LINE STUDIES
Benchmark phase III trials have highlighted the limitations
of conventional cytotoxic chemotherapy, drug resistance,
and addition of single-agent biologics. Key paradigms with
the potential to transform first-line treatment emphasize the
integration of antiangiogenics, PARP inhibitors, and im-
mune checkpoint inhibitors, exploiting shared pathway
interactions.
Preclinical evidence of synergy between antiangiogenic
agents and PARP inhibitors derives from cancer cell lines
that demonstrate hypoxia-induced downregulation of HRD
genes (and the potential for this to result in increased PARP
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inhibitor sensitivity).72,73 In vivo models have also demon-
strated that PARP-1 gene knockout or PARP inhibition
results in reduced angiogenesis.74 In patients with relapsed
platinum-sensitive high-grade serous or endometrioid
ovarian cancer, administration of cediranib (a multi-VEGFR
TKI) in combination with olaparib was associated with
a prolongation in PFS, compared with olaparib alone, with
a particularly marked effect in BRCA WT patients.75 This
observation led to randomized trials such as PAOLA-1
combining antiangiogenic agents with PARP inhibitors as
first-line maintenance, with an emphasis on patients
without germline or somatic BRCA mutations.
The efficacy of single-agent immune checkpoint inhibitors
in relapsed ovarian cancer has been disappointing to date.
The possibility that efficacy may be superior in the first-line
setting has been explored in the JAVELIN Ovarian 100 trial
of avelumab in combination with and/or as a maintenance
treatment after carboplatin plus paclitaxel chemotherapy in
previously untreated patients with stage III or IV ovarian
cancer. Although results have not been formally reported,
an interim analysis suggests that the study will not
achieve superiority in the prespecified primary end point
of PFS. There does remain interest in antiangiogenic-
immunotherapy combinatorial strategies to block tumor-
associated VEGF, which can interfere with normal dendritic
cell maturation, largely mediated through VEGFR1.76
Bevacizumab has also been shown to enhance CD8
lymphocyte localization within tumors and alter expression
of major histocompatibility complex and chemokines as-
sociated with the antitumor immune response, particularly
when administered in combination with anti–programmed
death ligand 1 (PD-L1) antibodies.77 Phase III trials are
currently evaluating combinations of bevacizumab with
immune checkpoint inhibitors during front-line therapy and
maintenance postchemotherapy, with data anticipated
to emerge over the next 3 years. IMagyn050 (GOG 2015/
ENGOT [European Network of Gynaecological Onco-
logical Trial Groups] OV39; ClinicalTrials.gov identifier:
NCT03038100) is one such trial; it randomly assigns pa-
tients to carboplatin, paclitaxel, bevacizumab, and either
atezolizumab or placebo (with both bevacizumab and
atezolizumab or placebo being administered concomitantly
with chemotherapy and as a maintenance).
The PARP inhibitor–immunotherapy combination has
perhaps generated the most interest of late. Germline
BRCA1- or BRCA2-mutated HGSC has increased neo-
antigen load, PD-1/PD-L1 expression, and lymphocyte
infiltration compared with BRCA WT cancers.78 These
features, along with the suggestion that PARP inhibi-
tors upregulate PD-L1 expression and enhance tumor-
associated immunosuppression in breast cancer, provide
some rationale for combining PARP inhibitors and immune
checkpoint inhibitors.79 A small phase I/II trial (MEDIOLA
[MEDI4736 in Combination With Olaparib in Patients
With Advanced Solid Tumors]; ClinicalTrials.gov identifier:
NCT02734004) combining olaparib and durvalumab
demonstrated a 70% response rate in patients with re-
lapsed, platinum-sensitive, BRCA-mutated ovarian can-
cer.80 Currently, at least five large randomized phase III
studies of PARP inhibitors plus immune checkpoint in-
hibitors are now under way: ATHENA (rucaparib and
nivolumab; ClinicalTrials.gov identifier: NCT03522246),
DUO-O (Durvalumab-Olaparib in Ovarian Cancer;
olaparib and durvalumab; ClinicalTrials.gov identifier:
NCT03737643), FIRST (First-Line Ovarian Cancer Treat-
ment With Niraparib Plus TSR-042; niraparib and TSR042;
ClinicalTrials.gov identifier: NCT03602859), JAVELIN
OvarianPARP100 (talazoparib and avelumab; ClinicalTrials.gov
identifier: NCT03642132), and MK-7339-001/ENGOT-OV43
(olaparib and pembrolizumab; ClinicalTrials.gov identifier:
NCT03740165).
Key considerations related to ongoing research:
• Maximal benefit has been achieved with cytoreductive
surgery and conventional platinum-based chemo-
therapy, limited by the emergence of drug resistance.
• Addition of single agents targeting angiogenesis has
extended PFS without a clinically significant im-
provement in OS.
• The activity of single-agent PARP inhibitors seems
most significant in tumors with BRCA mutations or
HRD. In addition, improvements in PFS have not yet
translated to OS, and long-term outcomes are limited
by emergence of PARP resistance.
• Preclinical studies and early-phase clinical trials
have highlighted potential interactions between anti-
angiogenics, PARP inhibitors, and immune check-
point inhibitors, providing a basis for ongoing phase III
trials of targeted combinations together with primary
chemotherapy and/or first-line maintenance.
LIMITATIONS OF CURRENT EVIDENCE
Despite the progress in first-line treatment of ovarian
cancer, there remain a number of significant uncertainties.
It is now clear that ovarian cancer histologic subtypes differ
in terms of their cells of origin, molecular biology, che-
motherapy sensitivity, and clinical behavior. Many of the
pivotal trials discussed here are numerically dominated by
HGSC. As such, consideration must be given to the extent
to which the findings can be extrapolated to rarer subtypes,
which may have had low representation within the key
phase III trials.
Examples of this concept include the uncertainty sur-
rounding the use of postoperative chemotherapy in low-
grade serous ovarian cancer, a disease in which response
rate to classic platinum-based chemotherapy may be as
low as 5%.81 Instead, consideration could be given to the
use of aromatase inhibitors82 or bevacizumab83,84 based
upon historic disease-specific data, without prospective
randomized trials.. Another example of histology-related
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uncertainty surrounds the use of adjuvant chemotherapy in
early-stage CCC. The risk of relapse in patients with In-
ternational Federation of Gynecology and Obstetrics stage
IA or IB disease, as well as those with stage IC disease
resulting from capsular rupture, seems to be low, and the
benefit of adjuvant treatment in these patients may be
small.85 The extent of chemotherapy benefit in patients with
other stage IC disease and beyond is unclear, particularly
given that CCC is relatively chemotherapy resistant com-
pared with HGSC in the advanced-disease setting (where
disease is evaluable for response).
FUTURE DIRECTIONS
Immediate priorities for clinical research in the setting
of primary therapy include combination strategies with
antiangiogenic agents, PARP inhibitors, and immune
checkpoint inhibitors. For example, it is important to build
upon the success of SOLO1 front-line maintenance by
determining whether adjuvant PARP inhibition also has
significant efficacy in BRCA WT HGSC, whether molecular
selection is required (eg, determination of HRD), or whether
PARP inhibitor effectiveness can be enhanced through
combinations with antiangiogenic agents or immune
checkpoint inhibitors.
Current clinical trial paradigms generally rely on a reference
arm with one novel drug and then add additional novel
drugs in the primary treatment or maintenance setting,
limiting the discovery of novel markers of sensitivity to in-
dividual agents; instead, the outcome data are a measure of
the efficacy of the combination. However, the interrogation
of longitudinal patient samples, whether tumor specimens
or plasma cell-free DNA, may help identify inherent re-
sistance mechanisms, such as secondary mutations in
BRCA1/2 or RAD51C/D genes for patients treated with
PARP inhibitors, and facilitate individualization of care in
this way.86,87 Finally, greater understanding of the molec-
ular landscape of rare chemotherapy-resistant histologic
subtypes such as CCC and low-grade serous carcinoma is
required to improve first-line therapeutic options for these
patients.
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